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The effect of acute treatment with the new antiepileptic drug (AED) levetiracetam (Kepprar) on the frequency of interictal
epileptiform discharges (IEDs) was evaluated in a double-blind, placebo-controlled, crossover study with therapeutic drug
monitoring and serial electroencephalographic (EEG) observations. Acute (500 mg twice daily) and chronic (individualized,
500–1000 mg twice daily) doses of levetiracetam were administered as an add-on to current AED treatment. Efficacy was tested
by measuring the frequency of IEDs in EEG recordings and the number of seizures. A single acute dose of levetiracetam induced
a reduction of IEDs in eight out of ten patients. During the acute phase, an insufficient number of seizures occurred for analysis.
During chronic treatment over 8 weeks, seven patients showed a reduction in seizure frequency (responder rate), and one patient
remained seizure free. No correlation was seen between levetiracetam levels and IED frequency. Doses of levetiracetam of up
to 2000 mg/day were well tolerated, and no interactions were seen with concomitant AEDs.
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INTRODUCTION
Highly variable and unpredictable expression of the
clinical manifestations of epilepsy often confounds
assessment of the efficacy of antiepileptic drugs
(AEDs) in short-term studies. In generalized epilepsy
(at least in some syndromes), there is a strong
correlation between seizures and spontaneous or
provoked epileptiform spike-and-wave discharges in
an electroencephalogram (EEG). Furthermore, these
discharges have been used in the photosensitive model
as a surrogate measure of potential drug efficacy1, 2.
For partial epilepsies, the relation between seizures
and interictal epileptiform discharges (IEDs) is
more controversial, but some interictal epileptiform
activities have subtle clinical manifestations. It is
important to know whether a new AED can have an
effect on these IEDs, defined as a sharp transient,
easily distinguishable from the background, having a
duration of less than 70 milliseconds for a spike and
70–200 milliseconds for a sharp wave3–5.
Monitoring IED frequency to measure antiepileptic
activity is useful for the early assessment of potential
AEDs, since the effect of acute doses can be studied.
Suppression of IEDs is variably correlated with AED
plasma levels, depending on the AED6. Diazepam,
phenobarbital and phenytoin all show a correlation
between suppression of IEDs and AED plasma
concentration7–9, while carbamazepine and valproate
show a variable correlation10, 11.
Levetiracetam is a novel AED registered recently
in 22 countries, including the United States, the
European Union and Australia. Its efficacy in partial
seizures, broad-spectrum potential, good tolerability,
and nearly ideal pharmacokinetic profile make leve-
tiracetam a promising new agent12.
Studies in animal epilepsy models have demon-
strated antiepileptic and potential antiepileptogenic
action of levetiracetam. Unlike conventional AEDs,
levetiracetam is inactive in classical screening models
for acute seizures, such as maximal electroconvulsive
shock and pentylenetetrazol seizure tests, but provides
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Fig. 1: Study design.
potent protection against seizures in animal models
of partial and generalized epilepsy13. In patients with
photosensitive epilepsy, levetiracetam has been shown
to diminish or abolish sensitivity to photic stimuli.
Following a single dose of levetiracetam, patients
exhibited a long-lasting (up to 30 hours), initial dose-
dependent reduction in photosensitivity14.
The objective of this study was to determine the
efficacy of acute levetiracetam treatment on IEDs in
patients with partial epilepsy and evaluate the clinical
effect of chronic treatment with individualized doses.
METHODS
Patient selection
Ten (six female and four male) epilepsy patients with
partial seizures were included in this single-center
study. The primary criterion for patient selection was
expression of frequent IEDs in EEG recordings. Sub-
jects in this study were taking a stable regimen of at
most two concomitant AEDs, such as carbamazepine,
clobazam, phenytoin, primidone, valproate sodium,
and valproic acid.
Study design
This study was conducted in three phases (Fig. 1).
In the first phase, potential subjects were evaluated
for four weeks to acquire baseline data and determine
appropriateness for inclusion. Seizure count and
IED frequency in EEG were monitored, a general
medical history was taken, and subjects received a
physical examination, an electrocardiogram (ECG),
blood screen and urine analysis.
In the second phase, the acute treatment phase,
eligible patients received a single-day supply of
levetiracetam, 500 mg twice daily, or placebo in a
double-blind crossover design. In the first part of the
acute phase, five patients received levetiracetam and
five received placebo. EEGs were recorded with a
32-channel amplifier using collodium-fixed gold cup-
electrodes under standardized vigilance conditions.
One standard 20 minutes duration EEG consisted of
recordings under four different conditions: 5 minutes
in a relaxed state with eyes closed, 5 minutes of mental
activity, 5 minutes of forced hyperventilation and
5 minutes post-hyperventilation. Six EEG recordings
were taken at a rate of one every 3 hours following
dose administration. Blood samples to assess plasma
AED levels were also taken every 3 hours following
dose administration. EEGs were continuously sampled
by a data-processing computer and stored on an
optical disk. Spikes in the EEG were detected and
counted with an automatic spike-detection program
(MONITOR, Version 5.0, Stellate System, Montreal)
and visually edited by a blind reader.
After 2 to 6 days without study drug, the two
patient populations were switched so that the placebo
group now received levetiracetam and the previous
levetiracetam group received placebo. Again, each
patient underwent six EEG recordings and blood
samples were taken every 3 hours following drug
administration. A full blood screen and urinalysis were
conducted at the end of the acute phase.
The third phase consisted of 8 weeks of leve-
tiracetam chronic treatment. For the first 4 weeks,
levetiracetam was administered at a dosage of 500 mg
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twice daily. During the second 4-week period, the
levetiracetam dosage was adjusted up or down for
each individual, depending on the outcome of the
first 4-week session. Full blood screen and urinalysis
were conducted at the end of each 4-week session. At
the end of the chronic treatment phase, patients were
allowed to continue with levetiracetam treatment or to
gradually withdraw.
Assessment
The primary efficacy variable measured was the
percentage difference in the number of IEDs between
levetiracetam treatment (six EEGs) and placebo
treatment (six EEGs) during the acute treatment phase.
EEGs were therefore recorded at different times after
the dose intake and were analysed together for specific
conditions and for the whole. Secondary efficacy
variables included number of seizures and pharma-
cokinetic data (levetiracetam and AED plasma levels).
For assessing tolerability and safety, adverse events
were recorded and blood and urine were collected at
the end of every testing day during the acute period
and every 4 weeks during the chronic treatment period.
ECGs were performed at baseline, during the acute
treatment period and at the end of the study.
Statistical analysis
The comparison of the effects of levetiracetam against
placebo during the acute treatment phase was carried
out on the basis of the primary efficacy criterion. To
take into account the repeated measurements of IEDs
at non-constant time interval, the AUC of the number
of IEDs (the total of all test conditions, was computed
using the linear trapezoidal rule and analysed by the
two-period crossover analysis method15. The relation
between the number of IEDs and levetiracetam
plasma concentration at the same time point was
examined for the first EEG period (relaxed conditions)
using descriptive correlation methods. For the whole
treatment phase, the daily number of seizures was
calculated for each patient.
RESULTS
Demographic data
The demographic characteristics are shown in Table 1.
The average age of the 10 patients was 25 years
(range, 16 to 35 years). The age of first seizure ranged
from 6 weeks to 14 years. The etiology of epilepsy
was cryptogenic in five patients, and symptomatic
in the remaining patients (two postencephalitis, two
postperinatal brain damage, and one posttraumatic).
EEG
The percentage difference in AUC of IEDs between
levetiracetam treatment and placebo is summarized
in Table 2 for the different conditions and for the
entire EEGs, data from the six recordings being
pooled together. In eight of the ten patients, there
was a consistent and major decrease in the AUC
of IEDs following acute levetiracetam treatment.
While percentage differences in AUC of IEDs were
observed under all conditions, in most patients the
difference was more obvious during the awake stage.
No correlation was found between the AUC of IEDs
and the AUC of levetiracetam plasma levels.
Chronic treatment: seizure count
During the 8 weeks of chronic levetiracetam treatment,
the number of seizures per day in most patients
was low. However, five patients showed a decrease
(50% responder rate) in the number of seizures
per day with chronic treatment compared with
baseline response. One patient remained seizure free
throughout levetiracetam treatment, while this patient
had had seven seizures per month prior to treatment.
Safety
Acute treatment period
Levetiracetam was generally well tolerated with a dose
of 1000 mg during acute treatment. A total of six
adverse events were reported in four patients. Only
one of the adverse events, mild dizziness, was reported
by a patient following treatment with levetiracetam.
All other adverse events, including abdominal pain
and menstrual disorder, vomiting and urinary tract
infection, and nausea and vomiting, occurred during
the placebo period or after the placebo washout
period. With the exception of vomiting (moderate),
all adverse events were mild and considered possibly
related to treatment. There were no relevant changes
in concomitant AED plasma levels attributable to
levetiracetam.
Chronic treatment period
Levetiracetam was generally well-tolerated using up
to a maximum dose of 3000 mg/day. During 8 weeks
of treatment, 31 adverse events were reported. One
was severe (pain in the left ear), and none was clearly
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Table 1: Demographics.
Treatment number Gender Age Age at onset of Etiology Number of seizures Concomitant
and sequence (years) epilepsy (years) during last month treatment
LEV→ PLC
01 F 25 9 Unknown 6 PHT-VPA
03 F 25 11 Unknown 6 PHT
06 F 21 10 Unknown 12 PHT-CLB
08 M 24 1.5 Encephalitis 7 CBZ-VPA
10 F 18 10 Unknown 360 PHT-PRM
PLC→ LEV
02 F 32 14 Unknown 5 CBZ-CLB
04 M 16 3.5 Encephalitis 6 CBZ-VPA
05 M 31 7 Head injury 4 PHT-CLB
07 F 23 6 weeks Perinatal 150 NONE
asphyxia
09 M 35 6 Perinatal 17 PHT
asphyxia
CBZ = carbamazepine; CLB = clobazam; LEV = levetiracetam; PHT = phenytoin; PLC = placebo; PRM = primidone; VPA = valproic
acid.
Table 2: Percentage difference in AUC of IEDs between levetiracetam and placebo (expressed in % of placebo) following acute
treatment under various test conditions.
Post-
Patient Awake Counting Hyperventilation hyperventilation Total
45/01 NA NA NA NA −97%a
45/02 −62% −52% −53% 84% −56%
45/03 −37% −40% −28% 42% −36%
45/04 −70% +6% −14% −23% −30%
45/05 +143% +30% +58% +82% +72%
45/06 +174% +75% +85% +325% +119%
45/07 −72% −68% −72% −74% −71%
45/08 −64% −65% −77% −79% −71%
45/09 −76% −78% −70% −72% −72%
45/10 −92% −90% −74% −93% −83%
a For this patient, the number of discharges was not available for all conditions, thus only a ‘mean’, equal to the number of discharges divided
by the number of conditions has been used.
related to treatment. There were no ECG changes nor
significant changes in blood and urinalysis.
DISCUSSION AND CONCLUSIONS
In this Phase II study, levetiracetam reduced the
number of IEDs in epilepsy patients with partial
seizures and frequent IEDs. Eight out of 10 patients
treated with levetiracetam experienced a decrease in
IEDs compared with patients receiving placebo. These
findings are consistent with studies of diazepam,
phenobarbital, and phenytoin, which also show a
decrease or a suppression of paroxysmal response on
EEG6. IEDs in partial epilepsy are often more easily
recorded from temporal lobe epilepsy and could be
the EEG sign of an active electrogenesis16. On the
other hand, IEDs in generalized epilepsies appear to
be familial and to be related to some genetic trait17, 18
and could translate the EEG sign of hyperexcitability.
Seizures were not numerous enough to allow statis-
tical analysis. However, seizures were less numerous
in five patients treated with levetiracetam, suggesting
clinical efficacy. Levetiracetam was well tolerated, and
no patients dropped out because of adverse events
related to levetiracetam.
No correlation was found between the percentage
difference in AUC of IED frequency and levetiracetam
plasma levels. This is in contrast to findings on sup-
pression of the photoparoxysmal response, where the
initial suppression was dose dependent and correlated
with levetiracetam plasma levels. However, the effect
persisted even after serum levels of levetiracetam were
no longer recordable. A similar effect on generalized
spike-and-wave discharges has been described in
relation to valproic acid19–21. These findings with
levetiracetam strengthen the view that the mechanisms
for genetic photoparoxysmal spikes and interictal dis-
charges related to cryptogenic/symptomatic epilepsies
are different.
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